A percutaneous implantable prosthetic heart valve was developed, and after animal studies, the first human case was performed in a 57-year-old man with calcific aortic stenosis with cardiogenic shock. The implantation was performed with the use of an antegrade trans-septal approach after aortic valvuloplasty, and over a follow-up period of 4 months, the valvular function remained satisfactory. However, severe noncardiac complications occurred leading to death 17 weeks after implantation.